Literature DB >> 3351437

Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component.

P N Hawkins1, M J Myers, A A Epenetos, D Caspi, M B Pepys.   

Abstract

Highly specific, high-resolution scintigraphic images of amyloid-laden organs in mice with experimentally induced amyloid A protein (AA) amyloidosis were obtained after intravenous injection of 123I-labeled serum amyloid P component (SAP). Interestingly, a much higher proportion (up to 40%) of the injected dose of heterologous human SAP localized to amyloid and was retained there than was the case with isologous mouse SAP, indicating that human SAP binds more avidly to mouse AA fibrils than does mouse SAP. Specificity of SAP localization was established by the failure of the related proteins, human C-reactive protein and Limulus C-reactive protein, to deposit significantly in amyloid and by the absence of human SAP deposition in nonamyloidotic organs. However, only partial correlations were observed between the quantity of SAP localized and two independent estimates, histology and RIA for AA of the amount of amyloid in particular organs. It is not clear which of the three methods used reflects better the extent or clinical significance of the amyloid deposits but in vivo localization of radiolabeled SAP, detectable and quantifiable by gamma camera imaging, is apparently extremely sensitive. These findings establish the use of labeled SAP as a noninvasive in vivo diagnostic probe in experimental amyloidosis, potentially capable of revealing the natural history of the condition, and suggest that it may also be applicable generally as a specific targeting agent for diagnostic and even therapeutic purposes in clinical amyloidosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3351437      PMCID: PMC2188867          DOI: 10.1084/jem.167.3.903

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  34 in total

Review 1.  The pathogenesis and biochemistry of amyloidosis.

Authors:  A S Cohen; L H Connors
Journal:  J Pathol       Date:  1987-01       Impact factor: 7.996

2.  Tumour imaging using an improved method of DTPA-coupled monoclonal antibodies radiolabelled with metallic radionuclides.

Authors:  A A Epenetos; D Snook; G Hooker; J P Lavender; K E Halnan
Journal:  Lancet       Date:  1984-07-21       Impact factor: 79.321

Review 3.  Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein.

Authors:  M B Pepys; M L Baltz
Journal:  Adv Immunol       Date:  1983       Impact factor: 3.543

4.  Further characterization of amyloid-enhancing factor.

Authors:  M A Axelrad; R Kisilevsky; J Willmer; S J Chen; M Skinner
Journal:  Lab Invest       Date:  1982-08       Impact factor: 5.662

5.  A new method to classify amyloid fibril proteins.

Authors:  T Kitamoto; J Tateishi; K Hikita; H Nagara; I Takeshita
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

6.  Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours.

Authors:  A A Epenetos; K E Britton; S Mather; J Shepherd; M Granowska; J Taylor-Papadimitriou; C C Nimmon; H Durbin; L R Hawkins; J S Malpas; W F Bodmer
Journal:  Lancet       Date:  1982-11-06       Impact factor: 79.321

7.  Immunohistochemical demonstration of amyloid P component in cerebro-vascular amyloidosis.

Authors:  I F Rowe; O Jensson; P D Lewis; J Candy; G A Tennent; M B Pepys
Journal:  Neuropathol Appl Neurobiol       Date:  1984 Jan-Feb       Impact factor: 8.090

8.  Cerebral amyloid angiopathy in dementia and old age.

Authors:  M M Esiri; G K Wilcock
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-11       Impact factor: 10.154

9.  Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits.

Authors:  M L Baltz; D Caspi; D J Evans; I F Rowe; C R Hind; M B Pepys
Journal:  Clin Exp Immunol       Date:  1986-12       Impact factor: 4.330

10.  Studies of the in vivo synthesis and catabolism of serum amyloid P component (SAP) in the mouse.

Authors:  M L Baltz; R F Dyck; M B Pepys
Journal:  Clin Exp Immunol       Date:  1985-01       Impact factor: 4.330

View more
  25 in total

Review 1.  Amyloidosis.

Authors:  M F Khan; R H Falk
Journal:  Postgrad Med J       Date:  2001-11       Impact factor: 2.401

2.  SPECT imaging of peripheral amyloid in mice by targeting hyper-sulfated heparan sulfate proteoglycans with specific scFv antibodies.

Authors:  Jonathan S Wall; Tina Richey; Alan Stuckey; Robert Donnell; Arie Oosterhof; Toin H van Kuppevelt; Nicole C Smits; Stephen J Kennel
Journal:  Nucl Med Biol       Date:  2011-09-29       Impact factor: 2.408

3.  Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component.

Authors:  Simon E Kolstoe; Basil H Ridha; Vittorio Bellotti; Nan Wang; Carol V Robinson; Sebastian J Crutch; Geoffrey Keir; Riitta Kukkastenvehmas; J Ruth Gallimore; Winston L Hutchinson; Philip N Hawkins; Stephen P Wood; Martin N Rossor; Mark B Pepys
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-16       Impact factor: 11.205

4.  Development and evaluation of agents for targeting visceral amyloid.

Authors:  Jonathan S Wall; Alan Solomon; Stephen J Kennel
Journal:  Tijdschr Nucl Geneeskd       Date:  2011-12

5.  A primed state exists in vivo following histological regression of amyloidosis.

Authors:  P N Hawkins; M B Pepys
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

6.  Experimental amyloidosis in the hamster: correlation between hamster female protein levels and amyloid deposition.

Authors:  F W Snel; T A Niewold; M L Baltz; P R Hol; A M Van Ederen; M B Pepys; E Gruys
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

7.  Computational modeling of the relationship between amyloid and disease.

Authors:  Damien Hall; Herman Edskes
Journal:  Biophys Rev       Date:  2012-09

8.  Induction in mice of human light-chain-associated amyloidosis.

Authors:  A Solomon; D T Weiss; M B Pepys
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

9.  Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

Authors:  Karl Bodin; Stephan Ellmerich; Melvyn C Kahan; Glenys A Tennent; Andrzej Loesch; Janet A Gilbertson; Winston L Hutchinson; Palma P Mangione; J Ruth Gallimore; David J Millar; Shane Minogue; Amar P Dhillon; Graham W Taylor; Arthur R Bradwell; Aviva Petrie; Julian D Gillmore; Vittorio Bellotti; Marina Botto; Philip N Hawkins; Mark B Pepys
Journal:  Nature       Date:  2010-10-20       Impact factor: 49.962

10.  Studies of the structure and binding properties of hamster female protein.

Authors:  G A Tennent; M L Baltz; G D Osborn; P J Butler; G E Noble; P N Hawkins; M B Pepys
Journal:  Immunology       Date:  1993-12       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.